Avadel Pharmaceuticals

Yahoo Finance • 27 days ago

Avadel Pharmaceuticals Celebrates Five Years of Driving Growth in Sleep Research Funding

A Media Snippet accompanying this announcement is available by clicking on this link. DUBLIN, Sept. 16, 2025 (GLOBE NEWSWIRE) -- The American Academy of Sleep Medicine Foundation (AASM Foundation) and Avadel Pharmaceuticals are celebrat... Full story

Yahoo Finance • last month

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

DUBLIN, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved... Full story

Yahoo Finance • last month

Avadel Pharmaceuticals to Present New Data on LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension at World Sleep 2025

– 17 abstracts accepted, including one oral presentation – – Data from the REFRESH real-world study highlight efficacy of once-nightly sodium oxybate when switching from twice-nightly oxybates – – REFRESH study also highlights efficacy i... Full story

Yahoo Finance • last month

Avadel Pharmaceuticals Strengthens Sleep Medicine Portfolio with Exclusive License of Valiloxybate from XWPharma Ltd

– Expands Avadel’s pipeline with salt-free, artificial sweetener-free, once-at-bedtime oxybate for treatment of narcolepsy and idiopathic hypersomnia – – Initial pharmacokinetic (PK) and comparative bioavailability study to initiate in fo... Full story

Yahoo Finance • last month

Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

DUBLIN, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the fol... Full story

Yahoo Finance • 2 months ago

Avadel raises 2025 revenue guidance to $275M as LUMRYZ patient base grows 63% year-over-year

Earnings Call Insights: Avadel Pharmaceuticals (AVDL) Q2 2025 MANAGEMENT VIEW * CEO Gregory J. Divis highlighted that "we are incredibly pleased with the results we achieved in the second quarter, including growing patient demand with... Full story

Yahoo Finance • 2 months ago

Avadel Pharmaceuticals (NASDAQ:AVDL) Surges 6.3% in Pre-Market as Q2 Earnings Crush Estimates on Strong LUMRYZ Performance

Avadel Pharmaceuticals (NASDAQ:AVDL [https://www.chartmill.com/stock/quote/AVDL]) reported second-quarter 2025 financial results that exceeded analyst expectations, driving a positive market reaction in pre-market trading. The company’s st... Full story

Yahoo Finance • 2 months ago

Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter 2025 Financial Results on August 7

DUBLIN, Ireland, July 31, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live... Full story

Yahoo Finance • 3 months ago

Avadel Pharmaceuticals Receives Unanimous Appeals Court Affirmation for LUMRYZ FDA Approval

Avadel Pharmaceuticals (NASDAQ:AVDL) is one of the most undervalued small-cap stocks to buy according to analysts. On June 30, Avadel Pharmaceuticals announced that the US Court of Appeals for the District of Columbia Circuit (Appeals Cour... Full story

Yahoo Finance • 3 months ago

Avadel stock rises after appeals court upholds LUMRYZ approval

Investing.com -- Avadel Pharmaceuticals PLC (NASDAQ:AVDL) stock rose 4.7% after a U.S. appeals court unanimously upheld the FDA’s approval of LUMRYZ, the company’s once-at-bedtime treatment for narcolepsy, in litigation brought by Jazz Ph... Full story

Yahoo Finance • 3 months ago

Avadel Pharmaceuticals Announces Unanimous Appeals Court Decision Upholding FDA Approval of LUMRYZ in Narcolepsy in Administrative Procedure Act Litigation

DUBLIN, June 30, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced that, on Friday, June 27, 2025, the U.S. Court of Appeals fo... Full story

Yahoo Finance • 3 months ago

Avadel Pharmaceuticals faces board challenge from investor ASL Strategic Value - report

Investing.com -- Investor ASL Strategic Value Fund plans to urge shareholders to vote against Avadel Pharmaceuticals’ (NASDAQ:AVDL) entire board of directors, according to the The Wall Street Journal on Sunday. The investment firm intends... Full story

Yahoo Finance • 4 months ago

Avadel gets FDA's Orphan Drug status for sleep disorder treatment

[asian woman sleepless at night] PonyWang/E+ via Getty Images * Avadel Pharmaceuticals (NASDAQ:AVDL [https://seekingalpha.com/symbol/AVDL]) said on Thursday that its sleep disorder medication, Lumryz, got U.S. FDA's Orphan Drug status f... Full story

Yahoo Finance • 4 months ago

Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

DUBLIN, June 05, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that LUMRYZTM has been granted Orphan Drug Designation... Full story

Yahoo Finance • 5 months ago

Avadel Pharmaceuticals Expands Leadership Team with Appointment of Susan Rodriguez as Chief Operating Officer

DUBLIN, May 13, 2025 (GLOBE NEWSWIRE) -- DUBLIN, May 13, 2025 – Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the appointment of Susan Rodrigu... Full story

Yahoo Finance • 5 months ago

Appeals court reverses-in-part, vacates-in part ruling in Avadel-Jazz fight

The U.S. Court of Appeals for the Federal Circuit reversed-in-part, vacated-in part and remanded a prior ruling from the United States District Court for the District of Delaware in No. 1:21-cv-01594-GBW, a suit between Avadel Pharmaceutic... Full story

Yahoo Finance • 5 months ago

Avadel Pharmaceuticals Reports First Quarter 2025 Financial Results and Raises Guidance

-- Generated $52.5 million in net revenue from sales of LUMRYZ™, a 93% increase over the first quarter of 2024 -- -- 2,800 patients on LUMRYZ as of March 31, 2025, a net increase of 300 patients since December 31, 2024 and a 100% year ove... Full story

Yahoo Finance • 5 months ago

Avadel Pharmaceuticals Announces Favorable Ruling in Appeal of Delaware Court Injunction

- With this ruling, Avadel can seek and be granted FDA approval for LUMRYZ in Idiopathic Hypersomnia - - Federal Circuit decision permits new clinical trials and further development of LUMRYZ™ for the treatment of indications beyond narco... Full story

Yahoo Finance • 6 months ago

Avadel Pharmaceuticals Provides Update at Needham Virtual Healthcare Conference

DUBLIN, April 08, 2025 (GLOBE NEWSWIRE) --  Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today presented at the 24th Annual Needham Virtual Healthcare Confer... Full story

Yahoo Finance • 6 months ago

Avadel Pharmaceuticals to Present at the 24th Annual Needham Healthcare Conference

DUBLIN, April 01, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fire... Full story